Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 4Neutropenia 3Febrile Neutropenia 3Small Cell Lung Carcinoma 1Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk 1Malignant Solid Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1Chemotherapy-induced Neutropenia 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1iniparib 1Tamoxifen 1Paclitaxel 1Mastectomy, Segmental 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Cancer Female × pegylated granulocyte colony-stimulating factor × Clear all
NCT04554056 2022-12-02

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2/3 Completed
586 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡